Rapid Discovery of Pyrido[3,4-*d*]pyrimidine Inhibitors of Monopolar Spindle kinase 1 (MPS1) Using a Structure-Based Hybridization Approach

Paolo Innocenti,† Hannah L. Woodward,† Savade Solanki,† Sébastien Naud,† Isaac M. Westwood,†,‡ Nora Cronin,‡ Angela Hayes,† Jennie Roberts,† Alan T. Henley,† Ross Baker,† Amir Faisal,† Grace Wing-Yan Mak,† Gary Box,† Melanie Valenti,† Alexis De Haven Brandon,† Lisa O’Fee,† Harry Saville,† Jessica Schmitt,† Berry Matijssen,† Rosemary Burke,† Rob L. M. van Montfort,†,‡ Florence I. Raynaud,† Suzanne A. Eccles,† Spiros Linardopoulos,†,§ Julian Blagg† and Swen Hoelder†,\*

† Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics,

The Institute of Cancer Research, 15 Cotswold Road, Surrey, SM2 5NG, United Kingdom,

‡ Division of Structural Biology, The Institute of Cancer Research, 237 Fulham Road, London, SW3 6JB, United Kingdom,

§The Breakthrough Breast Cancer Research Centre, Division of Breast Cancer Research,

The Institute of Cancer Research, 237 Fulham Road, London, SW3 6JB, United Kingdom

**Abstract**

MPS1 plays a central role in the transition of cells from metaphase to anaphase and is one of the main components of the spindle assembly checkpoint (SAC). Chromosomally unstable cancer cells heavily rely on MPS1 to cope with the stress arising from abnormal numbers of chromosomes and centrosomes and are thus more sensitive to MPS1 inhibition then normal cells. We report the discovery and optimization of a series of novel pyrido[3,4-*d*]pyrimidine based inhibitors *via* a structure-based hybridization approach from our previously reported inhibitor CCT251455 and a modestly potent screening hit. Compounds in this novel series display excellent potency and selectivity for MPS1, which translates into biomarker modulation in an *in vivo* PK/PD human tumor xenograft model.

**Introduction**

Interfering with mitotic processes has been a successful therapeutic approach to fight cancer.[1](#_ENREF_1) One example of a mitotic target is MPS1 (monopolar spindle 1, also known as TTK), a dual-specificity kinase that occupies a central role in the transition from metaphase to anaphase and is one of the main components of the SAC.[2](#_ENREF_4) This kinase prevents cells from progressing through mitosis until the kinetochores are properly attached to the microtubules and are under the appropriate tension. Whilst this mechanism is important to ensure error-free DNA replication in normal tissues, aneuploid and chromosomally unstable cancer cells often overexpress and heavily rely on MPS1 to cope with the stress arising from abnormal numbers of chromosomes and centrosomes.[3](#_ENREF_8) Due to these findings, it is not surprising that MPS1 has been found to be upregulated in a number of tumor types[4](#_ENREF_11) and that higher levels correlate with a higher histological grade, aggressiveness and poorer patient survival in breast cancer, glioblastoma and pancreatic ductal adenocarcinoma.[4a](#_ENREF_11), [5](#_ENREF_15) Furthermore, PTEN-deficient breast cancer cell lines have been reported to be more sensitive to MPS1 depletion or kinase inhibition.[3b](#_ENREF_9), [6](#_ENREF_17)

Using advanced inhibitors, including our own CCT251455 (**4**, *vide infra*), *in vivo* proof of principle has recently been achieved and it has been shown that due to a relatively narrow therapeutic window, [5a](#_ENREF_15), [8](#_ENREF_25), [12b](#_ENREF_31), [13](#_ENREF_32) MPS1 inhibition is particular effective when used in combination for example with tubulin-targeting agents or CDK4/6 inhibitors.[14](#_ENREF_33)

A number of MPS1 inhibitors have been disclosed.[7](#_ENREF_18) These include AZ3146 (**1**),[7b](#_ENREF_19) the Myrexis compound MPI-0479605 (**2**)[8](#_ENREF_25) and the Nerviano compound NMS-P715 (**3**).[9](#_ENREF_26) Also described in the literature are 1*H*-pyrrolo[3,2-*c*]-pyridine CCT251455 (**4**),[10](#_ENREF_28) MPS-IN-3 (**5**),[5a](#_ENREF_15) CFI-401870 (**6**)[11](#_ENREF_29) and the Shionogi compounds (**7**, **8**) (**Figure 1**).[12](#_ENREF_30)



**Figure 1.** Published MPS1 inhibitors.

We have recently disclosed a series of 1*H*-pyrrolo[3,2-*c*]-pyridines that showed excellent potency in biochemical and cellular assays, exemplified by CCT251455 (**4**).[10](#_ENREF_28) To support the discovery of a clinical candidate, we aimed to complement these compounds with a second chemical series, featuring lower molecular weight and lipophilicity. More specifically we set out to discover an additional lead series that: a) showed potent inhibition of MPS1 in cellular assays (IC50 < 100 nM), b) showed very good ligand efficiency (L.E.),[15](#_ENREF_37) c) displayed excellent selectivity, in particular against other cell cycle kinases such as CDK2, Aurora A as well as B and more generally against the wider kinome, d) robustly modulated MPS1 activity in a human tumor xenograft PK/PD model and e) showed significant scope for further modification.

Herein we describe the rapid discovery of such a series by structure-based hybridization of the 1*H*-pyrrolo[3,2-*c*]-pyridine series and a modestly potent hit from a focused kinase library screen. We show that, compounds in this novel series display nanomolar potency and improved selectivity against MPS1, which translates well into biomarker modulation in an *in vivo* human tumor xenograft model.

**Chemistry**

The synthesis of isoquinolines **14**, **15a** and **15b** was carried out from the commercially available 5-bromo-3-chloroisoquinoline **9** through sequential Suzuki couplings and Buchwald reactions using suitable boronic acids or esters and the required anilines (**Scheme 1**).

**Scheme 1**. Synthesis of isoquinoline derivatives.a



a Reagents and conditions: a) furan-2-ylboronic acid or 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*-pyrazole, Na2CO3, Pd(dppf)Cl2.CH2Cl2, DME/water, μW, 105 °C; b) 4-methoxyaniline **12** or 2,4-dimethoxyaniline **13**, tBuXPhos, Pd2dba3, Cs2CO3, tBuOH/water, μW, 80-100 °C.

**Scheme 2**. Synthesis of pyrido[3,4-*d*]pyrimidine derivatives.a



a Reagents and conditions: a) 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*-pyrazole, Na2CO3, Pd(dppf)Cl2.CH2Cl2, THF/water, 65 °C (**17**); b) cyclopropyl boronic acid, K3PO4, Pd(OAc)2, PCy3, toluene/water, 95 °C (**18**); c) *m*-CPBA, CH2Cl2, rt; d) *N*-(4-methoxyphenyl)formamide **21** or *N*-(2,4-dimethoxyphenyl)formamide **22**, DMSO, Cs2CO3, 100 °C (**24a**,**b**); e) 2-methoxy-4-(1-methyl-1*H*-pyrazol-4-yl)aniline **23**, TFA, 1,2,3-trifluoroethanol, μW, 130 °C (**24c**,**d**); f) ArNHCHO (**26a-e**), NaH, THF, rt; g) 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*-pyrazole or phenyl boronic acid, Cs2CO3, Pd(PPh3)4, 1,4-dioxane/water, 100 °C.

Compounds **24a-d** and **28a-e** in the pyrido[3,4-*d*]pyrimidine series were prepared according to a previously described strategy which makes use of the novel 8-chloro-2-(methylthio)pyrido[3,4-*d*]pyrimidine building block **16**.[16](#_ENREF_38) Thus, reaction with 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*-pyrazole or cyclopropylboronic acid under Suzuki conditions yielded intermediates **17** and **18**. These thiomethyl derivatives were in turn oxidized to the corresponding sulfones using *m*-CPBA and subsequently coupled with the required anilines or formamides to afford compounds **24a-d** (**Scheme 2**). In the majority of cases though, the order of events was reversed. Oxidation of 8-chloro-2-(methylthio)pyrido[3,4-*d*]pyrimidine **16** yielded the corresponding sulfone **25**,[16](#_ENREF_38) which was coupled with a series of formamides furnishing chloro-intermediates **27a-e** (**Scheme 2**). Final compounds **28a-e** were obtained by means of palladium-catalyzed Suzuki couplings with commercially available boronic acids or esters. Pyrido[3,4-*d*]pyrimidines **33a** and **33b** were prepared by direct substitution of amines on the 8-chloro-2-(methylthio)pyrido[3,4-*d*]pyrimidine building block **16** (**Scheme 3**). The resulting thiomethyl derivatives **29** and **30** were oxidized to the corresponding sulfones **31** and **32** and subsequently coupled with the required formamides to afford final compounds **33a** and **33b**.

**Scheme 3**. Functionalization of pyrido[3,4-*d*]pyrimidine core.a



a Reagents and conditions: a) amine, NMP, 80-135 °C; b) *m*-CPBA, CH2Cl2, rt; c) 2-methoxy-4-(1-methyl-1*H*-pyrazol-4-yl)aniline **23**, TFA, 1,2,3-trifluoroethanol, μW, 130 °C.

Pyrido[3,4-*d*]pyrimidines **34a-h** were prepared from intermediate **27a**[16](#_ENREF_38) by displacement using the appropriate nucleophiles (**Scheme 4**). In one instance the synthetic strategy involved the use of known pyridone **35**[16](#_ENREF_38) as a starting material: *O*-alkylation in the presence of base and bromomethyl cyclopropane gave intermediate **36**. Oxidation using *m*-CPBA and subsequent coupling with formamide **26a**[16](#_ENREF_38) afforded pyrido[3,4-*d*]pyrimidine **38** (**Scheme 4**).

**Scheme 4**.Synthesis of derivatives containing 8-position *N*, *O* and *S* substituents.a




a Reagents and conditions: a) amine, NMP, 80-135 °C (**34a-e**, **g**, **h**); b) cyclohexyl thiol, K2CO3, DMF, rt (**34f**); c) Ag2CO3, bromomethyl cyclopropane, CHCl3, rt to 60 °C; d) *m*-CPBA, CH2Cl2, rt; e) *N*-(2-methoxy-4-(1-methyl-1*H*-pyrazol-4-yl)phenyl)formamide **26a**, NaH, THF, rt.

In all cases, formamides and anilines were commercially available (**12**, **13**, **21**) or could be synthesized by means of standard transformations (**22**, **23**[17](#_ENREF_39)and **26a-e**, see Experimental and Supporting Information for details). In every case, formylation was carried out by refluxing in formic acid.

**Results and discussion**

At the start of this work, relatively few inhibitors of MPS1 had been disclosed. In addition to our 1*H*-pyrrolo[3,2-*c*]-pyridine series,[10](#_ENREF_28) we had identified and co-crystallized 1*H*-pyrazolo[4,3-*c*]pyridine **39**, a modestly potent hit, during an initial screening campaign. This compound showed low molecular weight and acceptable ligand efficiency. Its co-crystal structure in MPS1 revealed that **39** binds in a complementary way to **4**, whereby the pyrazole moiety binds to the hinge region of the protein. The furan moiety occupies the same region as the carbamate in the 1*H*-pyrrolo[3,2-*c*]-pyridine series. The phenyl ring and aniline moiety also occupy similar parts of the binding pocket (**Figure 2**).[18](#_ENREF_40) Based on these results, we anticipated that **39** would represent a viable starting point for a second series but that extensive optimization of potency and selectivity would be required. In order to rapidly discover a new series, whilst utilizing previously gained SAR data, we merged the 1*H*-pyrrolo[3,2-*c*]-pyridine scaffold with the screening hit **39** (**Figure 3**). Docking suggested that both the isoquinoline and pyrido[3,4-*d*]pyrimidine scaffolds could serve as hinge-binder elements for such a hybrid series (**Figure 3**). The isoquinoline scaffold had the advantage that proof-of-concept molecules could be rapidly prepared due to well precedented chemistry and commercially available building blocks. The pyrido[3,4-*d*]pyrimidine scaffold, on the other hand, was attractive from the point of view of novelty, the significantly lower lipophilicity and the fact that it incorporated the additional pyridine nitrogen from screening hit **39**. This scaffold, however, required significant investigation into its synthesis.[16](#_ENREF_38) Our plan was thus to prepare a select number of proof-of-concept molecules based on the isoquinoline core and to expand into the less explored and more polar pyrido[3,4-*d*]pyrimidines when the initial isoquinolines showed promising activity and ligand efficiency.

We used our biochemical MPS1 assay at 10 µM ATP concentration and an MSD-based cellular assay that measured autophosphorylation of ectopically expressed MPS1 in HCT116 cells.[10](#_ENREF_28) In addition we routinely determined selectivity against CDK2 and Aurora A and B. We did not detect significant activity against either Aurora A or B throughout the series. These data are not shown but can be found in the Supporting Information. Furthermore, as the IC50 values of our inhibitors approached the enzyme concentrations and thus the limit of the dynamic range of our biochemical assay, we also determined the biochemical potency at a higher (1 mM) ATP concentration (*vide infra*). Our overall goal for this lead finding effort was to show that potent (biochemical IC50 < 20 nM at 1 mM ATP, cellular IC50 < 100 nM) and selective (> 100 fold against CDK2) compounds could be obtained which exhibit significantly lower molecular weight and improved ligand efficiency compared with the 1*H*-pyrrolo[3,2-*c*]-pyridine series. Moreover, our goal was to show robust activity in our PK/PD human tumor xenograft model.



**Figure 2**. Superimposed crystal structure of MPS1 (pale green) bound to **4** (carbon atoms colored pink), extracted from PDB code 4C4J, on the structure of MPS1 (not shown) bound to **39** (carbon atoms colored yellow), PDB code 5EHY, showing the complementary binding of the modestly potent hit **39** and MPS1 inhibitor **4** to the hinge region of MPS1.



**Figure 3**. Hybridization strategy for the development of a novel chemical series of inhibitors of MPS1, from previously reported inhibitor CCT251455 (**4**) and screening hit **39**.


The data for the initial set of compounds are summarized in **Table 1**. The MPS1 inhibition for **14** was modest (IC50 = 3.66 µM, **Table 1**, **Entry 1**) but replacing the furan with a pyrazole **15a** not only lowered lipophilicity but also gave a five-fold increase in potency (**Table 1**, **Entry 2**). Moreover, incorporating an additional methoxy group led to a significant gain in potency and the IC50 of **15b** reached our goal for an initial proof-of-concept compound. As seen with the 1*H*-pyrrolo[3,2-*c*]-pyridines,[10](#_ENREF_28) the latter greatly improved selectivity towards CDK2. The significant gain in potency can be ascribed to the interaction of the aniline’s 2-methoxy substituent with a small hydrophobic pocket formed by Lys529, Ile531, Gln541 and Cys604.[10](#_ENREF_28) This pocket is not present in most other kinases including CDK2, explaining the beneficial effect on kinase selectivity.

Having achieved satisfactory potency and ligand efficiency (L.E. for **15b** = 0.36) by merging the 1*H*-pyrrolo[3,2-*c*]-pyridine series and screening hit **39**, we investigated the less lipophilic pyrido[3,4-*d*]pyrimidine scaffold. Gratifyingly, 8-substituted 2-anilinopyrido[3,4-*d*]pyrimidines proved to be more potent than their isoquinoline counterparts, reaching the double digit nanomolar range despite significantly lower calculated logP (**Table 1**). Isoquinoline **15b** along with pyrido[3,4-*d*]pyrimidines **24a** and **24b** were next tested in an MSD-based cellular assay. Both **15b** and **24b** only showed modest inhibition of autophosphorylation of ectopically expressed MPS1 in HCT116 cells, most likely due to suboptimal biochemical potency. In the 1*H*-pyrrolo[3,2-*c*]-pyridine series introduction of a pyrazole substituent at the 4-position of the aniline caused a significant increase in biochemical and cellular potency.[10](#_ENREF_28) Gratifyingly, this structural modification also resulted in a further improvement in biochemical potency for the pyrido[3,4-*d*]pyrimidine series, with compound **24c** achieving a MPS1 IC50 = 0.008 µM and a MSD IC50 = 0.604 µM (**Table 1**, **Entry 6**).

**Table 1**. Biochemical and cellular data for initial proof-of-concept isoquinolines (**14**, **15a**, **15b**) and pyrido[3,4-*d*]pyrimidines (**24a-c**).

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Entry | Compd | Structure | Avg. Caliper MPS1 IC50 µM | | Avg. Caliper  CDK2 IC50 µM | Avg. MSD HCT116 IC50 µM | AlogP |
| 1 | 14 |  | 3.66 (1.36, 5.95) | | 31.1 | - | 4.57 |
| 2 | 15a |  | 0.657±0.08 | | 1.22 (1.54, 0.911) | - | 3.83 |
| 3 | 15b |  | 0.099±0.064 | | 85.5 | 2.77 (1.93, 3.61) | 3.81 |
| 4 | 24a |  | 0.139±0.048 | | 0.089±0.014 | > 10 | 2.89 |
| 5 | 24b |  | | 0.046±0.018 | 1.54±0.297 | 4.84±3.29 | 2.87 |
| 6 | 24c |  | 0.008±0.002 | | 1.28±0.405 | 0.604±0.162 | 3.06 |

We solved the co-crystal structure of isoquinoline **15b** and pyrido[3,4-*d*]pyrimidine **24b** in MPS1 (**Figure 4**). The two structures overlaid very well with the co-crystal structure of **4** (**Figure 4A** and **B**), binding to the hinge region through the same motif as seen with the 1*H*-pyrrolo[3,2-*c*]-pyridines. This reinforced our initial hypothesis that merging the 1*H*-pyrrolo[3,2-*c*]-pyridine series and **39** would give a suitable starting point for an additional series of inhibitors. The aniline portion of all compounds overlaps as well as the 5-position and 8-position substituents of the isoquinolines and pyrido[3,4-*d*]pyrimidines respectively, occupying the same region as the carbamate group of **4**. Of note is the difference in conformation for **15b** and **24b** (**Figure 4C** and **D**). The introduction of two extra nitrogen atoms into the aromatic ring, and thus removal of two hydrogen atoms, results in a much more planar structure for the pyrido[3,4-*d*]pyrimidine **24b**. We measured the dihedral angles for both of these compounds - isoquinoline **15b** exhibits a dihedral angle of 108° and pyrido[3,4-*d*]pyrimidine **24b** exhibits a dihedral angle of 19° (**Figure 4D**). The more co-planar conformation of pyrido[3,4-*d*]pyrimidines mirrors the co-planar conformation of the carbamate function of **4** and is likely to be at least partially responsible for the improved activity seen with the much less lipophilic pyrido[3,4-*d*]pyrimidines. Based on these co-crystal structures, we had confidence that with further optimization we would achieve potent and selective pyrido[3,4-*d*]pyrimidine based inhibitors of MPS1.



**Figure 4**.(**A**) Superimposed crystal structure of MPS1 (pale green) bound to **4** (carbon atoms colored pink), extracted from PDB code 4C4J, on the structure of MPS1 (not shown) bound to **15b** (carbon atoms colored cyan), PDB code 5EI6. (**B**) Superimposed crystal structure of MPS1 (pale green) bound to **4** (carbon atoms colored pink), extracted from PDB code 4C4J, on the structure of MPS1 (not shown) bound to **24b** (green), PDB code 5EI2. (**C**) Superimposed crystal structure of MPS1 (pale green) bound to **15b** (carbon atoms colored cyan), extracted from PDB code 5EI6, on the structure of MPS1 (not shown) bound to **24b** (carbon atoms colored green) bound, PDB code 5EI2, showing the extent of the conformational difference between the isoquinolines and pyrido[3,4-*d*]pyrimidine scaffolds. (**D**) Measured dihedral angles for **15b** (cyan) and **24b** (green). **15b** exhibits a dihedral angle of 108° and **24b** exhibits a dihedral angle of 19°.

Through our hybridization strategy and exploration of the pyrido[3,4-*d*]pyrimidine scaffold, we achieved a potent inhibitor (**24c**, MPS1 IC50 = 0.008 µM) and for the first time reached significant levels of cellular inhibition with IC50 values below 1 µM. Compound **24c** represented a promising starting point for further optimization of this compound into a novel series of MPS1 inhibitors.


Since our initial goal was to show *in vivo* proof-of-concept in a human tumor xenograft model in mice, we investigated the stability of **24c** in mouse liver microsomes. Unfortunately, **24c** showed high turnover (Avg. MLM = 73% following 30 min incubation) and was not suitable for *in vivo* experiments. Metabolite ID studies suggested loss of a methyl group and we suspected that the methoxy aniline substituent was most likely to be the site of demethylation. This methoxy group was important for both potency and selectivity. After consideration of the x-ray crystal structures we had in hand, suggesting that larger substituents at this position would be tolerated, we prepared and tested a series of compounds in which this putative metabolic soft spot was replaced with similar moieties (**Table 2**). The majority of these compounds showed higher IC50 values than **24c** with the exception of the ethoxy derivative **28c**, which achieved comparable potency, whilst exhibiting significantly improved CDK2 selectivity (> 35 fold) and MLM stability (Avg. MLM = 45%). This increase in selectivity is likely due to the fact that the aniline 2-position substituent occupies a small lipophilic pocket present in MPS1, mentioned previously, consisting of Lys529, Ile531, Gln541 and the gatekeeper+2 residue Cys604. This pocket is not available in CDK2 due to the presence of the bulkier gatekeeper residue Phe82. The larger ethoxy 2-position **28c** substituent clashes with the CDK2 gatekeeper+2 residue, resulting in a better selectivity window than is seen for the methoxy derivative **24c**.

**Table 2.** Biochemical, cellular and mouse microsomal turnover data for compounds bearing alternative aniline substituents.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Entry | Compd | Structure | Avg. Caliper MPS1 IC50 µM | Avg. Caliper CDK2 IC50 µM | Avg. MSD HCT116 IC50 µM | Avg. MLM  %  (30 min) | AlogP |
| 1 | 24c |  | 0.008±  0.002 | 1.28±  0.405 | 0.604±  0.162 | 73 | 3.06 |
| 2 | 28b |  | 0.024±  0.014 | 0.38 (0.17, 0.59) | 2.54±0.789 | 63 | 3.56 |
| 3 | 28c |  | 0.010±  0.0033 | > 45 | 2.64±0.335 | 45 | 3.41 |
| 4 | 28d |  | 0.049 (0.067, 0.030) | >10 | - | 45 | 3.78 |
| 5 | 28e |  | 0.141±  0.049 | - | - | 59 | 2.93 |

Unfortunately, **28c** was five-fold less active in the cellular assay, which, given the similar biochemical potency and physicochemical properties, was difficult to rationalize. Whilst we regarded the ethoxy as a valuable alternative for the methoxy group with significantly improved selectivity and reduced risk of dealkylative reactive intermediate formation, we nevertheless decided to maintain the methoxy in place due to the improved cellular activity. Instead, we looked to improve the metabolic stability through modifications at the 8-position of the pyrido[3,4-*d*]pyrimidine core. We hypothesized that by introducing diverse substituents at this position of the scaffold the molecular recognition of the compounds by metabolic enzymes would be affected, leading to increased stability.

In order to address these aspects we used the structural information gathered on pyrido[3,4-*d*]pyrimidine **24c.** The crystal structure of this inhibitor showed that the 8-position pyrazole group binds to a hydrophobic pocket formed by Ile531, Val539, Met671 and Pro673 (**Figure 5A**). This is the same pocket that is occupied by the carbamate group of **4** and is sufficiently large to accommodate a variety of hydrophobic groups (**Figure 5B**). It is also of note that the co-crystal structure of **24c** shows ordering of the activation loop of MPS1, as is seen with CCT251455 (**4**).[10](#_ENREF_28) We thus prepared and tested a small set of compounds with different pyrazole replacements including a saturated pyrrolidine ring.



**Figure 5.** (**A**) Crystal structure of MPS1 (pale green) bound to **24c** (carbon atoms colored orange), extracted from PDB code 5EI8, showing residues (Ile531, Val539, Met671 and Pro673) present in the hydrophobic pocket occupied by 8-position pyrazole. (**B**) Superimposed crystal structure of MPS1 (pale green) bound to **24c** (carbon atoms colored orange), extracted from PDB code 5EI8, on the structure of MPS1 (not shown) bound to **4** (carbon atoms colored pink), PDB code 4C4J, showing that this is the same pocket occupied by the carbamate group of **4** (carbon atoms colored pink).

The data for these compounds are summarized in **Table 3**. The phenyl substituted derivative (**28a**) showed comparable potency in the biochemical and cellular assay and, despite higher lipophilicity, improved microsomal stability. The cyclopropyl derivative **24d** lost considerable activity, possibly due to the fact that this group is too small to engage in significant hydrophobic interactions. Interestingly, replacement of the pyrazole with a saturated pyrrolidine (**33a**) led to an equipotent compound in the biochemical assay. All compounds showed more than fifty-fold selectivity against CDK2.

**Table 3**. Biochemical, cellular and mouse microsomal turnover data for compounds bearing alternative 8-position substituents.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Entry | Compd | Structure | Avg. Caliper MPS1 IC50 µM | Avg. Caliper CDK2 IC50  µM | Avg. MSD HCT116 IC50  µM | Avg. MLM  %  (30 min) | AlogP |
| 1 | 24c |  | 0.008±0.002 | 1.28±0.405 | 0.604±0.162 | 73 | 3.06 |
| 2 | 28a |  | 0.018±0.006 | > 100 | 0.482±0.100 | 40 | 4.41 |
| 3 | 24d |  | 0.11±0.02 | 9.74 (12.55, 6.93) | 7.81±6.18 | 51 | 3.50 |
| 4 | 33a |  | 0.010±0.003 | 2.83±0.765 | 2.20±1.71 | 64 | 3.62 |

Of the compounds presented in **Table 3**, we considered the pyrrolidine derivative (**33a**) as the most promising for further optimization. A saturated moiety offered more possibilities to optimize the three-dimensional hydrophobic interaction in this subpocket compared with an aromatic ring where substituents can only be placed in the plane of the ring. Furthermore, increasing the number of sp3 centers has been suggested as a general approach to improve solubility and drug-like properties.[19](#_ENREF_41) We thus prepared a series of compounds with saturated substituents in this position.

**Table 4**. Biochemical, cellular and mouse microsomal turnover data for compounds bearing saturated substituents at the 8-position.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Entry | Compd | Structure | Avg. Caliper MPS1 IC50 µM | Avg. Caliper MPS1 IC50  (1 mM ATP) µM | Avg. Caliper CDK2 IC50 µM | Avg. MSD HCT116 IC50 µM | Avg. MLM  %  (30 min) | AlogP |
| 1 | 33a |  | 0.010±  0.003 | 0.325±  0.180 | 2.83±  0.76 | 2.20±  1.71 | 64 | 3.62 |
| 2 | 33b |  | 0.062±  0.010 | >1 (n=2) | - | - | - | 3.86 |
| 3 | 34a |  | 0.016±  0.0076 | 0.373±  0.145 | 0.852±  0.402 | 0.650±  0.167 | 66 | 4.00 |
| 4 | 34b |  | 0.012±  0.0048 | 0.127 (0.175, 0.0786) | 0.194±  0.041 | 0.224±  0.062 | 22 | 4.67 |
| 5 | 34c |  | 0.046±  0.015 | >1 (n=2) | - | - | - | 5.00 |
| 6 | 34d |  | 0.011±  0.0043 | 0.278±  0.158 | 1.08±  0.69 | 0.426±  0.057 | 33 | 3.63 |
| 7 | 34e |  | 0.018±  0.017 | 0.045±  0.023 | 0.445±  0.211 | 0.141 (0.146, 0.135) | 31 | 4.27 |
| 8 | 34f |  | 0.245±  0.125 | nd | >100 | nd | - | 5.40 |
| 9 | 38 |  | 0.148 (0.098, 0.198) | nd | - | - | - | 3.80 |

Importantly, since the IC50 values of many compounds were now approaching the enzyme concentration and thus the limit of the dynamic range of the assay, we complemented the MPS1 kinase assay at 10 µM with testing at 1 mM ATP. It has been demonstrated that increasing the ATP concentration shifts the IC50 values of ATP competitive inhibitors to higher readings, therefore increasing the dynamic range of the assay.[20](#_ENREF_42)

Compound **33b** incorporating a diethylamine substituent was significantly (six-fold) less potent in the 1 mM ATP Caliper assay than the pyrrolidine **33a** (**Table 4**). This is likely due to a higher free energy penalty when binding to the target for this less constrained compound. Gratifyingly, several amine substituents not only showed comparable biochemical potency but also improved microsomal stability, now in an acceptable range of 30% turnover whilst maintaining at least a hundred-fold selectivity against CDK2.


Since saturated amines were well tolerated in this position, we next prepared and tested derivatives in which the alkyl groups were linked through a sulfur or oxygen atom (**34f** and **38**). Remarkably, both lost significant activity (at least ten-fold) compared to the corresponding amine derivative. It is difficult to reconcile the pronounced loss of activity of compounds **34f**  and **38** with the wide range of both primary and secondary amines that are tolerated. Computational conformational analysis did not suggest a significant difference in the conformational preference of the oxygen and sulfur linked substituents compared to the amine substituents. Furthermore, analysis of the available crystal structure did not support the hypothesis that this difference may be driven by different hydrogen bond pattern e.g. to water molecules.

Several amino substituted compounds did however show potent IC50 values suggesting significant scope for further modifications. The neopentyl derivative **34e** was particularly promising due to its cellular potency combined with selectivity and improved mouse microsomal stability. As is apparent from the MPS1 IC50 at 1 mM ATP it was also the most potent derivative in this series. We thus followed up by synthesizing the two enantiomers **34g** and **34h** which differ from the neopentyl **34e** by an additional methyl group. We speculated that a slight increase in bulk could further improve lipophilic interactions and affect the preferred torsion angles. Particularly the (*S*)-enantiomer (**34h**) translated into an additional gain in biochemical and cellular potency compared with neopentyl derivative **34e**, achieving cellular modulation of MPS1 in the sub 100 nM range (**Table 5**). **34h** showed sufficient selectivity over CDK2 and very good microsomal stability (Avg. MLM = 27%).

**Table 5.** Biochemical, cellular and mouse microsomal turnover data for enantiomers **34g** and **34h**.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Entry | Compd | Structure | Avg. Caliper MPS1 IC50  µM | Avg. Caliper MPS1 IC50  (1 mM ATP) µM | Avg. Caliper CDK2 IC50 µM | Avg. MSD HCT116 IC50 µM | Avg. MLM  (30 min) | AlogP |
| 1 | 34e |  | 0.018±  0.017 | 0.045±  0.023 | 0.445±211 | 0.141 (0.146, 0.135) | 31 | 4.27 |
| 2 | 34g |  | 0.0224±  0.0137 | 0.419±  0.232 | 0.468±  0.25 | 0.187±  0.083 | 25 | 4.65 |
| 3 | 34h |  | 0.0112±  0.0046 | 0.0201±  0.013 | 0.56 (0.71, 0.41) | 0.059±  0.022 | 27 | 4.65 |

To rationalize the SAR we solved the structure of neopentyl **34e** (**Figure 6**). **Figure 6** shows that the bulkier, more hydrophobic neopentyl substituent of **34e** addresses the hydrophobic pocket first mentioned in **Figure 5A** to a greater extent than the pyrazole substituent of **24c**.  The slight increase in biochemical and cellular potency seen with **34h**, is likely to be driven by the increase in lipophilicity (4.65 vs 4.27).



**Figure 6**. Superimposed crystal structure of MPS1 (pale green) bound to **24c** (carbon atoms colored orange), extracted from PDB code 5EI8, on the structure of MPS1 (not shown) bound to **34e** (carbon atoms colored blue), PDB code 5EH0, showing the hydrophobic pocket formed by Ile531, Val539, Met671 and Pro673. The bulkier neopentyl substituent of **34e** addresses the pocket to a greater extent than the pyrazole substituent of **24c**


With **34h** we had achieved our initial potency goal in the biochemical and cellular assay. Especially considering its moderate molecular weight of 432 Dalton, **34h** represented an extremely potent MPS1 inhibitor with an IC50 = 0.0201 µM at high 1 mM ATP and a GI50 value in HCT116 cells of 0.15 µM. Furthermore, the combined SAR suggested significant scope for additional modifications to further optimize the series. This pyrido[3,4-*d*]pyrimidine (**34h**) was selective towards Aurora A and B (Supporting Information **Table S1**) and PLK1 (IC50 > 100 µM), as well as against a wide panel of kinases (Supporting Information **Table S2-S4**) and did not inhibit CYP or hERG (Supporting Information **Table S5**+**S6**). Pyrido[3,4-*d*]pyrimidine **34h**, showing low turnover in mouse and rat liver microsomes (27 and 24%, after 30 min incubation, respectively), was progressed through to mouse and rat PK experiments despite a 70% turnover in human liver microsomes. The resulting data showed moderate clearance (28 and 24 mL/min/kg in mouse and rat respectively) and high oral bioavailability (68 and 100% in mouse and rat respectively) with moderate to high volumes of distribution (**Table 6**).

**Table 6**. Mouse and rat blood pharmacokinetics of **34h** at 5 mg/kg iv and po.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Species | t1/2 (h) | Cl (mL/min/kg) | PPB (%) | Vss (L/kg) | F (%) |
| mouse | 8.2 | 28 | 99.98 | 14.7 | 68 |
| rat | 2.5\* | 24 | 99.97 | 4.64 | 100 |

\* Only detected to 4 h.

Finally, we performed a 3 day pharmacokinetic/pharmacodynamic (PK/PD) study to determine whether biomarker modulation could be achieved *in vivo*. MPS1 inhibition results in premature exit of cells from mitosis,[7e](#_ENREF_22) and we therefore chose the mitotic marker phospho-histone H3 as a readout. Histone H3 is specifically phosphorylated at Ser 10 during mitosis.[21](#_ENREF_43) Gratifyingly, oral administration of 100 mg/kg of **34h** BID for 3 days to mice bearing HCT116 human colon carcinoma xenografts caused a reduction of the phospho-histone H3 levels compared with vehicle control treated animals at 2 and 6 h, which is consistent with MPS1 inhibition (**Figure 7**).



**Figure 7**. (**A**,**B**) Representative immunoblots of phospho-histone H3 showing dose-dependent PD modulation in HCT116 human tumor xenografts, following 100 mg/kg BID dosing of **34h** for 3 consecutive days. Total histone H3, cleaved poly ADP ribose polymerase (PARP, a measure of apoptosis) and glyceraldehyde 3-phosphate dehydrogenase (GADPH, for protein loading) are also shown. (**C**) Phospho-histone H3 *versus* total histone H3 ratio for control and treated samples at 2 and 6 h after last dose, statistical significance also shown.

Pyrido[3,4-*d*]pyrimidine **34h** showed strong modulation of the PD biomarkers and as such fulfilled all of the criteria we had initial set as well as showing significant scope for further modification. We thus nominated **34h** as an advanced lead compound.

**Conclusions**

By merging two distinct chemical series, namely 1*H*-pyrrolo[3,2-*c*]-pyridines and 1*H*-pyrazolo[4,3-*c*]pyridines, we successfully fulfilled our aim to discover a new class of MPS1 inhibitors based on a pyrido[3,4-*d*]pyrimidine core. The discovery and optimization of this previously unprecedented core was guided by structure-based design. The use of the pyrido[3,4-*d*]pyrimidine scaffold granted access to potent inhibitors with reduced size and lipophilicity compared with the parent 1*H*-pyrrolo[3,2-*c*]-pyridines. Our optimized compound **34h** proved to be extremely potent in the MPS1 biochemical assay with the ability to target this kinase in cells with significant growth inhibition. A screen against a large sample of the human kinome revealed a high level of selectivity, especially with regard to mitotic kinases. Most importantly, pyrido[3,4-*d*]pyrimidine **34h** showed a satisfactory pharmacokinetic profile in rodents and was effective in inhibiting MPS1 activity *in vivo*. **34h** fulfilled all of the criteria we had initial set and showed significant scope for further modification. We thus nominated **34h** as an advanced lead compound. Optimization of the remaining issues in particular HLM instability, high lipophilicity and plasma protein binding, as well as the investigation of advanced compounds in efficacy models as both a single therapy and in combination, will be reported in due course.

**Experimental Section**

**General Chemistry Information.** Starting materials, reagents and solvents for reactions were reagent grade and used as purchased. Chromatography solvents were HPLC grade and were used without further purification. Thin layer chromatography (TLC) analysis was performed using silica gel 60 F-254 thin layer plates. Flash column chromatography was carried out using columns pre-packed with 40-63 μm silica. Microwave assisted reactions were carried out using a Biotage Initiator microwave system. LCMS and HRMS analyses were performed on a HPLC system with diode array detector operating at 254 nm, fitted with a reverse-phase 50×4.6 mm column at a temperature of 22 °C, connected to a Time of Flight (ToF) mass spectrometer (ESI). The following solvent system, at a flow rate of 2 mL/min, was used: solvent A: methanol; solvent B: 0.1% formic acid in water. Gradient elution was as follows: 1:9 (A:B) to 9:1 (A:B) over 2.5 min, 9:1 (A:B) for 1 min then reversion back to 1:9 (A:B) over 0.3 min, 1:9 (A:B) for 0.2 min. 1H NMR spectra were recorded on a Bruker Avance 500 MHz spectrometer using an internal deuterium lock. NMR data is given as follows: chemical shift (δ) in ppm, multiplicity, coupling constants (*J*) given in Hz and integration. The purity of final compounds was determined by HPLC as described above and is ≥ 95% unless specified otherwise.

Compounds **2-Methoxy-4-(1-methyl-1*H*-pyrazol-4-yl)aniline 23**,[17](#_ENREF_39) **8-chloro-2-(methylsulfonyl)pyrido[3,4-*d*]pyrimidine** **25**,[16](#_ENREF_38) ***N*-(2-Methoxy-4-(1-methyl-1*H*-pyrazol-4-yl)phenyl)formamide 26a**[16](#_ENREF_38), **8-Chloro-*N*-(2-methoxy-4-(1-methyl-1*H*-pyrazol-4-yl)phenyl)pyrido[3,4-*d*]pyrimidin-2-amine 27a**[16](#_ENREF_38) and **2-(methylthio)pyrido[3,4-d]pyrimidin-8(7H)-one** **35**[16](#_ENREF_38) were synthesized using previously published procedures.

**3-Chloro-5-(furan-2-yl)isoquinoline 10**

A suspension of 5-bromo-3-chloroisoquinoline **9** (58 mg, 0.24 mmol), furan-2-ylboronic acid (32 mg, 0.29 mmol) and Pd(dppf)Cl2.CH2Cl2 (20 mg, 0.024 mmol) in DME (0.5 mL) and sodium carbonate (2 M, 0.24 mL) was heated to 105 °C under microwave irradiation for 1 h. The mixture was concentrated onto silica gel and purified by flash column chromatography (0 - 50% EtOAc in cyclohexane) to give the title compound (41 mg, 75%). HRMS (ESI)*m/z* calcd forC13H9ClNO(M+H) 230.0367, found 230.0343. 1H NMR (500 MHz, CDCl3) δ 9.09 (s, 1H), 8.33 (s, 1H), 7.99 - 7.90 (m, 2H), 7.71 - 7.55 (m, 2H), 6.79 (dd, *J* = 3.4, 0.6 Hz, 1H), 6.62 (dd, *J* = 3.4, 1.8 Hz, 1H).

**3-Chloro-5-(1-methyl-1*H*-pyrazol-4-yl)isoquinoline 11**

A suspension of 5-bromo-3-chloroisoquinoline **9** (300 mg, 1.24 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*-pyrazole (309 mg, 1.49 mmol) and Pd(dppf)Cl2.CH2Cl2 (105 mg, 0.124 mmol) in DME (2.5 mL) and sodium carbonate (2 M, 1.24 mL) was heated to 105 °C under microwave irradiation for 1.5 h. The mixture was concentrated onto silica gel and purified by flash column chromatography (0 - 100% EtOAc in cyclohexane) to give the title compound (324 mg, quant.). HRMS (ESI)*m/z* calcd forC13H11ClN3 (M+H) 244.0636, found 244.0639. 1H NMR (500 MHz, CDCl3) δ 9.08 (s, 1H), 7.96 (s, 1H), 7.90 (d, *J* = 8.1 Hz, 1H), 7.73 (s, 1H), 7.67 - 7.55 (m, 3H), 4.05 (s, 3H).

**5-(Furan-2-yl)-*N*-(4-methoxyphenyl)isoquinolin-3-amine 14**

A suspension of 3-chloro-5-(furan-2-yl)isoquinoline **10** (41 mg, 0.18 mmol), 4-methoxyaniline **12** (29 mg, 0.23 mmol), cesium carbonate (204 mg, 0.626 mmol), *t*BuXPhos (30 mg, 0.071 mmol), Pd2(dba)3 (16 mg, 0.018 mmol) and *t*BuOH (3% H2O) (1 mL) was heated to 80 °C under microwave irradiation for 3 h. The mixture was concentrated onto silica gel and purified by flash column chromatography (0 - 100% EtOAc in cyclohexane) to give the title compound (10 mg, 18%). HRMS (ESI)*m/z* calcd forC20H17N2O2 (M+H) 317.1285, found 317.1282. 1H NMR (500 MHz, CDCl3) δ 8.95 (s, 1H), 7.84 - 7.75 (m, 2H), 7.61 (s, 1H), 7.57 (s, 1H), 7.58 - 7.25 (m, 3H), 7.17 - 6.90 (m, 2H), 6.77 - 6.60 (m, 2H), 6.54 (dd, *J* = 3.3, 1.8 Hz, 1H), 3.85 (s, 3H).

***N*-(4-Methoxyphenyl)-5-(1-methyl-1*H*-pyrazol-4-yl)isoquinolin-3-amine 15a**

A suspension of 3-chloro-5-(1-methyl-1*H*-pyrazol-4-yl)isoquinoline **11** (55 mg, 0.23 mmol), 4-methoxyaniline **12** (36 mg, 0.29 mmol), cesium carbonate (257 mg, 0.789 mmol), *t*BuXPhos (38 mg, 0.090 mmol), Pd2(dba)3 (21 mg, 0.023 mmol) and *t*BuOH (3% H2O) (1 mL) was heated to 80 °C under microwave irradiation for 1.5 h. The mixture was concentrated onto silica gel and purified by flash column chromatography (0 - 100% EtOAc in cyclohexane) to give the title compound (6 mg, 8%). HRMS (ESI)*m/z* calcd forC20H19N4O(M+H) 331.1553, found 331.1546. 1H NMR (500 MHz, CDCl3) δ 8.95 (s, 1H), 7.75 (d, *J* = 8.2 Hz, 1H), 7.68 (s, 1H), 7.52 (s, 1H), 7.50 - 7.46 (m, 2H), 7.31 - 7.21 (m, 3H), 7.03 - 6.89 (m, 2H), 6.48 (s, 1H), 3.98 (s, 3H), 3.83 (s, 3H).

***N*-(2,4-Dimethoxyphenyl)-5-(1-methyl-1*H*-pyrazol-4-yl)isoquinolin-3-amine 15b**

A suspension of 3-chloro-5-(1-methyl-1*H*-pyrazol-4-yl)isoquinoline **11** (55 mg, 0.23 mmol), 2,4-dimethoxyaniline **13** (45 mg, 0.29 mmol), cesium carbonate (257 mg, 0.789 mmol), *t*BuXPhos (38 mg, 0.090 mmol), Pd2(dba)3 (21 mg, 0.023 mmol) and *t*BuOH (3% H2O) (1 mL) was heated to 80 °C under microwave irradiation for 1.5 h and then to 100 °C for 1.5 h. The mixture was concentrated onto silica gel and purified by flash column chromatography (0 - 100% EtOAc in cyclohexane) to give the title compound (22 mg, 27%). HRMS (ESI)*m/z* calcd forC21H21N4O2 (M+H) 361.1659, found 361.1661. 1H NMR (500 MHz, CDCl3) δ 8.96 (s, 1H), 7.78 - 7.69 (m, 2H), 7.61 (d, *J* = 8.6 Hz, 1H), 7.54 (s, 1H), 7.47 (dd, *J* = 7.0, 1.0 Hz, 1H), 7.33 - 7.23 (m, 2H), 6.73 (s, 1H), 6.58 - 6.49 (m, 2H), 3.99 (s, 3H), 3.85 (s, 3H), 3.83 (s, 3H).

**Preparation of compounds in Scheme 2 (Exemplified by the preparation of compounds 24a, 24d, 28a and 28b).**

**8-(1-Methyl-1*H*-pyrazol-4-yl)-2-(methylthio)pyrido[3,4-*d*]pyrimidine 17**

A solution of 8-chloro-2-(methylthio)pyrido[3,4-*d*]pyrimidine **16** (480 mg, 2.27 mmol), (1-methyl-1*H*-pyrazol-4-yl)boronic acid pinacol ester (940 mg, 4.52 mmol) and Pd(dppf)Cl2.CH2Cl2 (100 mg, 0.122 mmol) in THF (15 mL) and sodium carbonate (2 M, 5 mL) was heated to 65 °C for 18 h. The mixture was diluted with EtOAc and quenched with brine. The aqueous layer was extracted with EtOAc three times. The combined organics were washed with water, brine, dried and concentrated *in vacuo*. The residue was purified by flash column chromatography (0 - 4% MeOH in CH2Cl2) to give the title compound (658 mg, quant). HRMS (ESI) *m/z* calcd for C12H12N5S (M+H) 258.0813, found 258.0817. 1H NMR (500 MHz, CDCl3) δ 9.22 (s, 1H), 8.67 (s, 1H), 8.63 - 8.56 (m, 2H), 7.47 (d, *J* = 5.3 Hz, 1H), 4.05 (s, 3H), 2.78 (s, 3H).

**8-(1-Methyl-1*H*-pyrazol-4-yl)-2-(methylsulfonyl)pyrido[3,4-*d*]pyrimidine 19**

A suspension of 8-(1-methyl-1*H*-pyrazol-4-yl)-2-(methylthio)pyrido[3,4-*d*]pyrimidine **17** (584 mg, 2.27 mmol) in CH2Cl2 (22 mL) was treated with *m*-CPBA (77% w/w, 1.12 g, 4.98 mmol) at 0 °C and then allowed to reach rt over 18 h. The mixture was quenched with water and extracted with CH2Cl2. The combined organics were washed with water, dried and concentrated *in vacuo*. The residue was purified by flash column chromatography (0 - 100% EtOAc in cyclohexane) to give the title compound (408 mg, 62%). HRMS (ESI) *m/z* calcd for C12H12N5O2S (M+H) 290.0706, found 290.0722. 1H NMR (500 MHz, (CD3)2SO) δ 10.00 (s, 1H), 8.91 (d, *J* = 5.4 Hz, 1H), 8.81 (s, 1H), 8.53 (s, 1H), 7.99 (d, *J* = 5.4 Hz, 1H), 3.99 (s, 3H), 3.59 (s, 3H).

***N*-(4-Methoxyphenyl)-8-(1-methyl-1*H*-pyrazol-4-yl)pyrido[3,4-*d*]pyrimidin-2-amine 24a**

To a solution of 8-(1-methyl-1*H*-pyrazol-4-yl)-2-(methylsulfonyl)pyrido[3,4-*d*]pyrimidine **19** (29 mg, 0.10 mmol) in DMSO (4 mL) was added cesium carbonate (59 mg, 0.18 mmol) and *N*-(4-methoxyphenyl)formamide (15 mg, 0.10 mmol). The mixture was heated to 100 °C for 18 h. The mixture was diluted with EtOAc and water. The aqueous layer was re-extracted with EtOAc. The combined organics were washed with brine, dried and concentrated *in vacuo*. The residue was purified by flash column chromatography (0 - 10% MeOH in CH2Cl2), followed by SCX-2 cartridge (MeOH - 1 M NH3 in MeOH) to give the title compound (8 mg, 24%). HRMS (ESI) *m/z* calcd C18H16N6O (M+H) 333.1464, found 333.1450. 1H NMR (500 MHz, CD3OD) δ 9.24 (s, 1H), 8.38 (s, 1H), 8.29 (d, *J* = 5.4 Hz, 1H), 7.63 – 7.59 (m, 3H), 7.54 (d, *J* = 5.4 Hz, 1H), 7.05 (d, *J* = 8.9 Hz, 2H), 3.91 (s, 3H), 3.87 (s, 3H).

**8-Cyclopropyl-2-(methylthio)pyrido[3,4-*d*]pyrimidine 18**

A solution of 8-chloro-2-(methylthio)pyrido[3,4-*d*]pyrimidine **16** (20 mg, 0.094 mmol), cyclopropyl boronic acid (11 mg, 0.13 mmol), PCy3 (3 mg, 11 µmol), K3PO4 (70 mg, 0.32 mmol) and Pd(OAc)2 (1.0 mg, 4.5 µmol) was dissolved in toluene/water (6:1, 1 mL) and heated to 95 °C for 18 h. The mixture was diluted with EtOAc and quenched with brine. The aqueous layer was extracted with EtOAc three times. The combined organics were washed with water, brine, dried and concentrated *in vacuo*. The residue was purified by flash column chromatography (0 - 20% EtOAc in cyclohexane) to give the title compound (13 mg, 62%). HRMS (ESI) *m/z* calcd C11H12N3S (M+H) 218.0746, found 218.0751. 1H NMR (500 MHz, CDCl3) δ 9.18 (s, 1H), 8.46 (d, *J* = 5.4 Hz, 1H), 7.37 (d, *J* = 5.5 Hz, 1H), 3.46 (tt, *J* = 8.2, 4.8 Hz, 1H), 2.74 (s, 3H), 1.34 - 1.27 (m, 2H), 1.25 - 1.17 (m, 2H).

**8-Cyclopropyl-2-(methylsulfonyl)pyrido[3,4-*d*]pyrimidine 20**

A suspension of 8-cyclopropyl-2-(methylthio)pyrido[3,4-*d*]pyrimidine **18** (127 mg, 0.584 mmol) in CH2Cl2 (5 mL) was treated with *m*-CPBA (77% w/w, 290 mg, 1.29 mmol) at 0 °C and then allowed to reach rt over 18 h. The mixture was quenched with water and extracted with CH2Cl2. The combined organics were washed with water, dried and concentrated onto silica. The residue was purified by flash column chromatography (0 - 70% EtOAc in cyclohexane) to give the title compound (128 mg, 88%). HRMS (ESI) *m/z* calcd C11H12N3O2S (M+H) 250.0645, found 250.0648. 1H NMR (500 MHz, (CD3)2SO) δ 9.99 (s, 1H), 8.79 (d, *J* = 5.5 Hz, 1H), 7.94 (d, *J* = 5.5 Hz, 1H), 3.56 (s, 3H), 3.44 (m, 1H), 1.30 - 1.25 (m, 2H), 1.24 - 1.20 (m, 2H).

**8-Cyclopropyl-*N*-(2-methoxy-4-(1-methyl-1*H*-pyrazol-4-yl)phenyl)pyrido[3,4-*d*]pyrimidin-2-amine 24d**

A solution of 2-methoxy-4-(1-methyl-1*H*-pyrazol-4-yl)aniline **23** (50 mg, 0.25 mmol), TFA (45 µL, 0.60 mmol) and 8-cyclopropyl-2-(methylsulfonyl)pyrido[3,4-*d*]pyrimidine **20** (31 mg, 0.12 mmol) in 2,2,2-trifluoroethanol (0.7 mL) was heated to 130 °C under microwave irradiation for 1.5 h. The reaction was diluted with EtOAc and quenched with aqueous sat. sodium bicarbonate. The aqueous layer was extracted with EtOAc and the combined organics were washed with water, brine, dried and concentrated *in vacuo*. The residue waspurified by flash column chromatography (0 - 60% EtOAc in cyclohexane) to give the title compound (20 mg, 43%). HRMS (ESI) *m/z* calcd for C21H21N6O (M+H) 373.1771, found 373.1773. 1H NMR (500 MHz, (CD3)2SO) δ 9.40 (s, 1H), 8.54 (s, 1H), 8.41 (d, *J* = 8.3 Hz, 1H), 8.28 (d, *J* = 5.3 Hz, 1H), 8.17 (d, *J* = 0.9 Hz, 1H), 7.90 (d, *J* = 0.8 Hz, 1H), 7.56 (d, *J* = 5.3 Hz, 1H), 7.30 (d, *J* = 1.8 Hz, 1H), 7.25 (dd, *J* = 8.2, 1.8 Hz, 1H), 3.96 (s, 3H), 3.88 (s, 3H), 3.24 (m, 1H), 1.16 - 1.08 (m, 4H).

***N*-(2-Methoxy-4-(1-methyl-1*H*-pyrazol-4-yl)phenyl)-8-phenylpyrido[3,4-*d*]pyrimidin-2-amine 28a**

To a solution of 8-chloro-*N-*(2-methoxy-4-(1-methyl-1*H*-pyrazol-4-yl)phenyl)pyrido[3,4-*d*]pyrimidin-2-amine **27a**[16](#_ENREF_38) (25 mg, 0.068 mmol) in 1,4-dioxane/water (2:1, 3 mL) was added phenyl boronic acid (17 mg, 0.14 mmol), Pd(PPh3)4 (16 mg, 0.014 mmol) and cesium carbonate (33 mg, 0.10 mmol). The reaction was heated to 100 °C under microwave irradiation for 30 min. The reaction was diluted with EtOAc and water, dried and concentrated *in vacuo*. The residue was purified by flash column chromatography (0 - 100% EtOAc in cyclohexane) followed by SCX-2 cartridge (MeOH - 1 M NH3 in MeOH) to give the title compound (8 mg, 29%). HRMS (ESI) *m/z* calcd for C24H21N6O (M+H) 409.1777, found 409.1771. 1H NMR (500 MHz, CD3OD) δ 9.37 (s, 1H), 8.56 (d, *J* = 8.5 Hz, 1H), 8.50 (d, *J* = 5.5 Hz, 1H), 8.11 - 8.09 (m, 2H), 7.97 (s, 1H), 7.82 (s, 1H), 7.79 (d, *J* = 5.5 Hz, 1H), 7.61 - 7.59 (m, 3H), 7.19 (d, *J* = 2.0 Hz, 1H), 6.99 (dd, *J* = 8.5, 2.0 Hz, 1H), 4.02 (s, 3H), 3.95 (s, 3H).

**8-Chloro-*N*-(2-methyl-4-(1-methyl-1*H*-pyrazol-4-yl)phenyl)pyrido[3,4-*d*]pyrimidin-2-amine 27b**

To a cooled (0 °C) suspension of *N*-(2-methyl-4-(1-methyl-1*H*-pyrazol-4-yl)phenyl)formamide **26b** (40 mg, 0.19 mmol) in THF (4 mL) was added sodium hydride (60% w/w dispersion in oil, 12 mg, 0.30 mmol). The reaction mixture was stirred at rt for 10 min. The mixture was cooled to 0 °C and 8-chloro-2-(methylthio)pyrido[3,4-*d*]pyrimidine **25**[16](#_ENREF_38) (60 mg, 0.24 mmol) was added. The mixture was stirred for 18 h whilst slowly warming to rt and then concentrated *in vacuo* and the residue partitioned between EtOAc and water. The aqueous layer was extracted with EtOAc and CH2Cl2. The combined organics were washed with water, brine, dried and concentrated *in vacuo*. The residue was purified by flash column chromatography (0 - 5% MeOH in EtOAc) to give the title compound (79 mg, 97%). HRMS (ESI) *m/z* calcd for C19H16ClN6 (M+H) 351.1119, found 351.1111. 1H NMR (500 MHz, CDCl3) δ 9.17 (s, 1H), 8.26 (d, *J* = 5.0 Hz, 1H), 7.79 (s, 1H), 7.63 (s, 1H), 7.52 (d, *J* = 5.0 Hz, 1H), 7.47 (dd, *J* = 8.0, 2.0 Hz, 1H), 7.42 (m, 1H), 7.39 (d, *J* = 2.0 Hz, 1H), 3.98 (s, 3H), 2.44 (s, 3H).

**8-(1-Methyl-1*H*-pyrazol-4-yl)-*N*-(2-methyl-4-(1-methyl-1*H*-pyrazol-4-yl)phenyl)pyrido[3,4-*d*]pyrimidin-2-amine 28b**

To a solution of 8-chloro-*N*-(2-methyl-4-(1-methyl-1*H*-pyrazol-4-yl)phenyl)pyrido[3,4-*d*]pyrimidin-2-amine **27b** (12 mg, 0.034 mmol) in 1,4-dioxane/water (2:1, 3 mL) was added 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*-pyrazole (14 mg, 0.068 mmol), cesium carbonate (17 mg, 0.051 mmol) and Pd(PPh3)4 (2 mg, 1.7 µmol). The reaction mixture was heated to 100 °C under microwave conditions for 30 min. The reaction mixture was diluted with EtOAc and water. The combined organics were washed with water, brine, dried and concentrated *in vacuo.* The residue was purified by flash column chromatography (0 - 15% MeOH in EtOAc) to give the title compound (7 mg, 52%). HRMS (ESI) *m/z* calcd for C22H21N8 (M+H) 397.1884, found 397.1878. 1H NMR (500 MHz, CDCl3) δ 9.16 (s, 1H), 8.43 (d, *J* = 5.5 Hz, 1H), 8.40 (d, *J* = 5.5 Hz, 2H), 7.86 (d, *J* = 8.0 Hz, 1H), 7.82 (s, 1H), 7.67 (s, 1H), 7.50 - 7.45 (m, 2H), 7.36 (d, *J* = 5.5 Hz, 1H), 7.05 (br s, 1H), 4.00 (s, 3H), 3.77 (s, 3H), 2.39 (s, 3H).

**Preparation of compounds in Scheme 3 (exemplified by the preparation of 33a).**

**2-(Methylsulfonyl)-8-(pyrrolidin-1-yl)pyrido[3,4-*d*]pyrimidine 31**

A mixture of 8-chloro-2-(methylthio)pyrido[3,4-*d*]pyrimidine **16** (105 mg, 0.496 mmol) and pyrrolidine (425 µL, 5.10 mmol) in NMP (2.5 mL) was stirred at 135 °C for 3 h. The mixture was quenched with aqueous sat. sodium bicarbonate and extracted with EtOAc. The combined organics were washed with water, brine, dried and concentrated *in vacuo* to afford the crude sulfide.

A suspension of crude sulfide **29** (ca. 0.496 mmol) in CH2Cl2 (4 mL) was treated with ​*m*-CPBA (77% w/w, 250 mg, 1.11 mmol) at 0 °C and then allowed to reach rt for 18 h. An additional portion of *m*-CPBA (77% w/w, 60 mg, 0.27 mmol) was added at rt and the mixture stirred for 2 h. The mixture was quenched with water and extracted with CH2Cl2. The combined organics were washed with aqueous sat. sodium bicarbonate, brine, dried and concentrated *in vacuo*. The residue was purified by flash column chromatography (0 - 70% EtOAc in cyclohexane) to give the title compound (62 mg, 45% over two steps). LCMS (ESI) *m/z* 279 (M+H). 1H NMR (500 MHz, (CD3)2SO) δ 9.62 (s, 1H), 8.30 (d, *J* = 5.4 Hz, 1H), 7.11 (d, *J* = 5.5 Hz, 1H), 3.97 (br s, 4H), 3.45 (s, 3H), 1.98 (s, 4H).

***N*-(2-Methoxy-4-(1-methyl-1*H*-pyrazol-4-yl)phenyl)-8-(pyrrolidin-1-yl)pyrido[3,4-*d*]pyrimidin-2-amine 33a**

A solution of 2-methoxy-4-(1-methyl-1*H*-pyrazol-4-yl)aniline **23** (52 mg, 0.26 mmol), TFA (50 µL, 0.65 mmol) and 2-(methylsulfonyl)-8-(pyrrolidin-1-yl)pyrido[3,4-*d*]pyrimidine **31** (35 mg, 0.13 mmol) in 2,2,2-trifluoroethanol (0.6 mL) was heated to 130 °C under microwave irradiation for 2 h. An additional portion of TFA (50 µL, 0.65 mmol) was added and the mixture was heated to 180 °C under microwave irradiation for 2 h. The reaction mixture was diluted with EtOAc, quenched with aqueous sat. sodium bicarbonate and the aqueous layer extracted with EtOAc. The combined organics were washed with water, brine, dried, concentrated *in vacuo* and purified by flash column chromatography (0 - 100% EtOAc in cyclohexane) to give the title compound (10 mg, 20%). HRMS (ESI) *m/z* calcd for C22H24N7O (M+H) 402.2037, found 402.2040. 1H NMR (500 MHz, (CD3)2SO) δ 9.12 (s, 1H), 8.37 (s, 1H), 8.14 (s, 1H), 7.88 (d, *J* = 0.9 Hz, 1H), 7.87 - 7.79 (m, 2H), 7.24 (d, *J* = 1.9 Hz, 1H), 7.17 (dd, *J* = 8.2, 1.9 Hz, 1H), 6.86 (d, *J* = 5.4 Hz, 1H), 3.89 (s, 3H), 3.87 (s, 3H), 3.84 - 3.76 (m, 4H), 1.91 - 1.81 (m, 4H).

**Preparation of compounds in Scheme 4 (exemplified by the preparation of compounds 34a, 34f and 38).**

***N*8-Isobutyl-*N*2-(2-methoxy-4-(1-methyl-1*H*-pyrazol-4-yl)phenyl)pyrido[3,4-*d*]pyrimidine-2,8-diamine 34a**

A mixture of 8-chloro-*N-*(2-methoxy-4-(1-methyl-1*H*-pyrazol-4-yl)phenyl)pyrido[3,4-*d*]pyrimidin-2-amine **27a** (27 mg, 0.074 mmol) and 2-methylpropan-1-amine (100 µl, 1.0 mmol) in NMP (0.7 mL) was stirred at 130 °C in a closed cap vial for 5 h. The reaction mixture was quenched with aqueous sat. sodium bicarbonate and extracted with EtOAc. The combined organics were washed with water, brine, dried and concentrated *in vacuo*. The residue was purified by flash column chromatography (0 - 80% EtOAc in cyclohexane) to give the title compound (19 mg, 63%). HRMS (ESI) *m/z* calcd for C22H26N7O (M+H) 404.2193, found 404.2177. 1H NMR (500 MHz, (CD3)2SO) δ 9.16 (s, 1H), 8.43 (s, 1H), 8.19 (d, *J* = 8.3 Hz, 1H), 8.15 (d, *J* = 0.8 Hz, 1H), 7.88 (d, *J* = 0.8 Hz, 1H), 7.77 (d, *J* = 5.7 Hz, 1H), 7.27 (d, *J* = 1.9 Hz, 1H), 7.18 (dd, *J* = 8.2, 1.9 Hz, 1H), 6.88 - 6.85 (m, 2H), 3.93 (s, 3H), 3.87 (s, 3H), 3.39 - 3.28 (m, 2H), 2.00 (hept, *J* = 6.8 Hz, 1H), 0.95 (d, *J* = 6.7 Hz, 6H).

**8-(Cyclohexylthio)-*N-*(2-methoxy-4-(1-methyl-1*H*-pyrazol-4-yl)phenyl)pyrido[3,4-*d*]pyrimidin-2-amine 34f**

A mixture of 8-chloro-*N-*(2-methoxy-4-(1-methyl-1*H*-pyrazol-4-yl)phenyl)pyrido[3,4-*d*]pyrimidin-2-amine **27a** (26 mg, 0.071 mmol) and potassium carbonate (15 mg, 0.11 mmol) in DMF (0.35 mL) was treated with cyclohexanethiol (12 µL, 0.098 mmol) and stirred at rt for 4 d. An additional batch of potassium carbonate (10 mg, 0.070 mmol) and cyclohexanethiol (12 µL, 0.098 mmol) were added and the mixture stirred at 50 °C for 18 h. The reaction was quenched with brine and extracted with EtOAc. The combined organics were washed with water, brine, dried and concentrated *in vacuo*. The residue was purified by flash column chromatography (0 - 80% EtOAc in cyclohexane) to give the title compound (30 mg, 94%). HRMS (ESI) *m/z* calcd for C24H27N6OS (M+H) 447.1962, found 447.1948. 1H NMR (500 MHz, (CD3)2SO) δ 9.35 (s, 1H), 8.55 (br s, 1H), 8.29 (d, *J* = 5.4 Hz, 1H), 8.20 (d, *J* = 0.9 Hz, 1H), 7.93 (d, *J* = 0.8 Hz, 1H), 7.48 (d, *J* = 5.4 Hz, 1H), 7.29 (d, *J* = 1.9 Hz, 1H), 7.26 (dd, *J* = 8.2, 1.9 Hz, 1H), 3.96 (br s, 4H), 3.87 (s, 3H), 2.17 - 2.05 (m, 2H), 1.82 – 1.72 (m, 2H), 1.65 (m, 1H), 1.59 - 1.40 (m, 4H), 1.35 (m, 1H).

**8-(Cyclopropylmethoxy)-2-(methylthio)pyrido[3,4-*d*]pyrimidine 36**

A suspension of 2-(methylthio)pyrido[3,4-*d*]pyrimidin-8(7*H*)-one **35**[16](#_ENREF_38) (502 mg, 2.60 mmol) and silver carbonate (988 mg, 3.58 mmol) in CHCl3 (25 mL) was treated with bromomethyl cyclopropane (310 µl, 3.19 mmol) and stirred at rt for 18 h. The mixture was heated to 60 °C for 4 h and an additional batch of bromomethyl cyclopropane (310 µl, 3.19 mmol) was added. The reaction was heated to 60 °C for 18 h. An additional batch of bromomethyl cyclopropane (310 µl, 3.19 mmol) was added and heated for a further 2 h. Et3N was added (6 mL), the mixture filtered through Celite (CH2Cl2) and concentrated *in vacuo*. The residue was purified by flash column chromatography (0 - 80% EtOAc in cyclohexane) to give the title compound (112 mg, 17%). LCMS (ESI) *m/z* 248 (M+H). 1H NMR (500 MHz, CDCl3) δ 9.14 (s, 1H), 8.07 (d, *J* = 5.6 Hz, 1H), 7.18 (d, *J* = 5.6 Hz, 1H), 4.43 (d, *J* = 7.0 Hz, 2H), 2.74 (s, 3H), 1.48 (m, 1H), 0.73 - 0.61 (m, 2H), 0.54 - 0.43 (m, 2H).

**8-(Cyclopropylmethoxy)-2-(methylsulfonyl)pyrido[3,4-*d*]pyrimidine 37**

A suspension of 8-(cyclopropylmethoxy)-2-(methylthio)pyrido[3,4-*d*]pyrimidine **31** (110 mg, 0.445 mmol) in CH2Cl2 (4 mL) was treated with *m*-CPBA (77% w/w, 325 mg, 1.35 mmol) at 0 °C and then allowed to reach rt for 18 h. The mixture was quenched with water and extracted with CH2Cl2. The combined organics were washed with aqueous sat. sodium bicarbonate, dried and concentrated *in vacuo*. The residue was purified by flash column chromatography (0 - 55% EtOAc in cyclohexane) to give the title compound (95 mg, 77%). HRMS (ESI) *m/z* calcd C12H14N3O3S (M+H) 280.0750, found 280.0748. 1H NMR (500 MHz, (CD3)2SO) δ 9.92 (s, 1H), 8.44 (d, *J* = 5.7 Hz, 1H), 7.72 (d, *J* = 5.7 Hz, 1H), 4.43 (d, *J* = 7.2 Hz, 2H), 3.50 (s, 3H), 1.41(m, 1H), 0.69 - 0.57 (m, 2H), 0.49 - 0.40 (m, 2H).

**8-(Cyclopropylmethoxy)-*N*-(2-methoxy-4-(1-methyl-1*H*-pyrazol-4-yl)phenyl)pyrido[3,4-*d*]pyrimidin-2-amine 38**

A solution of *N*-(2-methoxy-4-(1-methyl-1*H*-pyrazol-4-yl)phenyl)formamide **26a** (30 mg, 0.13 mmol) in THF (1 mL) was treated with sodium hydride (60% w/w dispersion in oil, 8 mg, 0.20 mmol) at 0 °C. After stirring for 40 min at rt, the mixture was cooled to 0 °C and 8-(cyclopropylmethoxy)-2-(methylsulfonyl)pyrido[3,4-*d*]pyrimidine **37** (46 mg, 0.17 mmol) was added. The reaction was allowed to reach rt and stirred for 18 h. Sodium hydroxide (2 M, 1 mL) and MeOH (1 mL) were added and the resulting mixture stirred at rt for 3 h. The volatiles were removed *in vacuo*. The residue was partitioned between EtOAc and water. The aqueous layer was extracted with EtOAc, and the combined organics were washed with water, brine, dried and concentrated *in vacuo*. The residue was purified by flash column chromatography (0 - 75% EtOAc in cyclohexane) to give the title compound (27 mg, 52%). HRMS (ESI) *m/z* calcd for C22H23N6O2 (M+H) 403.1877, found 403.1871. 1H NMR (500 MHz, (CD3)2SO) δ 9.31 (s, 1H), 8.61 (s, 1H), 8.39 (s, 1H), 8.17 (d, *J* = 0.8 Hz, 1H), 7.94 - 7.84 (m, 2H), 7.35 (d, *J* = 5.6 Hz, 1H), 7.28 (d, *J* = 1.8 Hz, 1H), 7.19 (dd, *J* = 8.3, 1.8 Hz, 1H), 4.33 (d, *J* = 6.9 Hz, 2H), 3.94 (s, 3H), 3.88 (s, 3H), 1.40 (m, 1H), 0.68 - 0.59 (m, 2H), 0.49 - 0.39 (m, 2H).

**Preparation of formamides 26b-e (Exemplified by preparation of compound 26b).**

***N*-(2-Methyl-4-(1-methyl-1*H*-pyrazol-4-yl)phenyl)formamide 26b**

A solution of 2-methyl-4-(1-methyl-1*H*-pyrazol-4-yl)aniline **S1** (100 mg, 0.534 mmol) in formic acid (3 mL) was heated to 100 °C for 3 h. The reaction mixture was concentrated *in vacuo*. The residue was partitioned between aqueous sat. sodium bicarbonate and EtOAc. The aqueous layer was re-extracted with EtOAc. The combined organics were washed with water, brine, dried and concentrated *in vacuo.* The residue was purified by flash column chromatography (0 - 10% MeOH in EtOAc) to give the title compound (160 mg, 34%). HRMS (ESI) *m/z* calcd for C12H14N3O (M+H) 216.1131, found 216.1141. 1H NMR (500 MHz, CD3OD) δ 8.31 (s, 1H), 7.93 (s, 1H), 7.80 (s, 1H), 7.67 (d, *J* = 8.0 Hz, 1H), 7.44 (d, *J* = 2.0 Hz, 1H), 7.38 (dd, *J* = 8.0, 2.0, Hz, 1H), 3.92 (s, 3H), 2.31 (s, 3H).

**Biochemical assays**. MPS1, CDK2 and Aurora A and B counterscreen assays were performed as reported previously.[10](#_ENREF_28)

**MSD assay**. IC50 of MPS1 auto-phosphorylation inhibition at pTpS33/37 sites in HCT116 cells was determined by an electrochemiluminescence assay (mesoscale discovery, MSD) as described previously.[10](#_ENREF_28)

**Crystallisation**

The kinase domain (residues 519-808) of MPS1 was produced in *E. coli* and purified as described previously.[7c](#_ENREF_20) For compound **39**, apo crystals of MPS1 were grown in PEG300 as previously described[10](#_ENREF_28) prior to soaking in a fresh solution containing 35% PEG300, 1 mM inhibitor and 1% (*v/v*) DMSO for 24 h. The crystal was cryo-protected in soak solution supplemented with 22.5% ethylene glycol prior to flash cooling in liquid nitrogen.

Co-crystals of MPS1 with compound **S11** were grown at 18 ℃ using the sitting-drop vapour-diffusion method. The crystallization drops were composed of 2 μL of protein/ligand solution (8.9 mg/mL protein and 5 mM **S11**) and 2 μL of reservoir solution placed over 200 μL of reservoir solution of 18-26% (*w/v*) PEG3350, 0.1 M Bis-Tris propane pH 7.5, 0.1 M MgCl2 and 0.1 M sodium formate in 48-well plates. Co-crystals typically grew in 12-16 h. Crystals of MPS1 with **S11** were transferred to backsoaking solutions containing reservoir solution also containing 200 mM of inhibitor and up to 20% (*v/v*) DMSO and incubated at 18 ℃ for 24-48 h. Crystals were cryo-protected with paratone-N oil prior to flash cooling in liquid nitrogen.

Co-crystals of MPS1 with compound **34e** were grown grown at 18 oC using the sitting-drop vapour-diffusion method. The crystallization drops were composed of 2 μL of protein/ligand solution (11.4 mg/mL protein and 2 mM **34e**) with 20% *(w/v)* PEG3350, 0.1 M Bis-Tris propane pH 7.5, 0.2 M Sodium formate. Crystals were cryo-protected with paratone-N oil prior to flash cooling in liquid nitrogen.

**Data collection, structure solution and refinement**

X-ray diffraction data were collected at 100K at Diamond Light Source (Oxfordshire, UK), or in-house on a Rigaku FRX with Pilatus 300K detector. Data were integrated with XDS[22](#_ENREF_45) or MOSFLM (**S11** dataset only).[23](#_ENREF_46) All data were imported to MTZ format with POINTLESS,[24](#_ENREF_47) then scaled and merged with AIMLESS[24](#_ENREF_47) in the CCP4 suite.[23](#_ENREF_46) The structures were solved by molecular replacement with PHASER,[25](#_ENREF_48) with the PDB structure 4C4J[10](#_ENREF_28) as the search model after removal of all non-protein atoms. Structures were refined in iterative cycles of model building with COOT[26](#_ENREF_49) and refinement with BUSTER.[27](#_ENREF_50) TLS groups were selected with PHENIX phenix.find\_tls\_groups.[28](#_ENREF_51) Ligand restraints were generated with GRADE[29](#_ENREF_52) and MOGUL.[30](#_ENREF_53) The final structure quality was checked with MOLPROBITY.[31](#_ENREF_54) The data collection and refinement statistics are presented in **Table S7**.

**Microsomal metabolism**.Microsomal turnover was carried out in male CD1 mice, female Sprague Dawley rats and pooled human liver microsomes obtained from Tebu-Bio (Peterborough, U.K.) following 30 min incubation of 10 µM compound in 1 mg/mL microsomal protein, 3 mmol/L MgCl2, 1 mmol/L NADPH, 2.5 mmol/L, UDP-glucuronic acid, and 10 mmol/L phosphate buffer (pH 7.4) (all purchased from Sigma Aldrich, Gillingham, U.K). Reactions, at 37 °C, were started by addition of the test compound and were terminated at 0 and 30 min by the addition of 3 volumes of ice-cold methanol containing internal standard. Samples were centrifuged at 2,800 x g for 30 min at 4 °C and the supernatants analyzed. Control incubations were prepared as above with omission of cofactors. Compound measurements were performed by LCMS on an Agilent quadrupole time of flight instrument (Agilent 6510) following separation with a 6 min gradient of 10 mM ammonium acetate in methanol on a 5 cm x 2.1 2.6 µm particles C18 column (Kinetex Phenomenex). For metabolite identification, the gradient was extended to 20 min and MS/MS carried out with fragment elucidation for ions of interest.

**Pharmacokinetic studies**. All *in vivo* studies were performed in accordance with UK Home Office regulations, ICR ethical review processes and UK National Cancer Research Institute guidelines.[32](#_ENREF_55) Female Balb/C mice and Sprague Dawley rats were obtained from Charles River (Harlow, UK). Animals were adapted to laboratory conditions for at least 1 week prior to dosing and were allowed food and water *ad libitum*. Compounds were administered iv or po (0.1 mL/10g in 10% DMSO, 5% tween 20 in saline). Blood samples were collected from the tail vein (20 µL) at 8 time points over the 24 h post dose and spotted on Whatman B cards together with a standard curve and quality controls spiked in control blood. Cards were allowed to dry at rt for at least 6 h. Cards were punched and 6 mm discs were extracted with 200 µL methanol containing 500 nM Olomoucine as an internal standard. Following centrifugation, extracts were analyzed by multiple reaction monitoring of precursor and product ions by ESI-LCMS/MS on a QTRAP 4000 (ABSciex) following separation as above. Quantitation was carried out with an external calibration (8 points ranging from 1 nM to 25 µM). Quality controls were included (3 concentrations) at the beginning and the end of the analytical run and were within 20% of nominal concentrations.

Pharmacokinetic parameters were derived from non-compartmental analysis WiniNONlin (model 200 and 201) Pharsight version.

***In vivo* proof-of-concept studies**.Animals (6-8 week old female NCr athymic mice) were supplied by a commercial breeder and fed sterilized food and water *ad libitum.*

**PK/PD study**. 3 million HCT116 human colorectal carcinoma cells were injected s.c. bilaterally into the flanks. Dosing commenced when tumors reached a mean diameter of 8-10 mm (day 14). Animals (n = 6 per group) were dosed twice daily with compound **34h** (100 mg/kg po) or vehicle (10% DMSO, 5% Tween 20, 85% saline) over 3 days(6 doses) and groups of three were culled at 2 or 6 h after the final dose. Heparinized plasma and tumor samples were collected for pharmacokinetic (PK) and pharmacodynamic (PD) biomarker analysis.

**PD assays**. For PD analysis, frozen tumor samples were homogenized in RIPA lysis buffer (150 mM NaCl, 50 mM Tris pH 7.5, 1 mM EDTA pH 8.0, 1% NP40, 1% sodium deoxycholate, 1% sodium dodecyl sulfate and supplemented with protease and phosphatase inhibitors), sonicated and centrifuged to clear the debris. Protein concentrations of the supernatants were measured and 5 g protein for each sample was loaded onto LDS-PAGE (Life technologies). Proteins were separated, transferred to nitrocellulose membrane and probed with phospho-histone H3 (Millipore), total-histone H3 (Abcam), cleaved-PARP (Cell Signaling) and GAPDH (Millipore) antibodies. Blots were quantified using Image J and analyzed with Graphpad Prism.

ASSOCIATED CONTENT

Supporting Information

Experimental procedures and analytical data for final compounds **24b**, **24c**, **28c**, **28d**, **28e**, **33b**, **34b-e**, **34g**, **34h**, intermediates and formamides. Aurora A and B inhibition data available for all compounds. CYP and hERG activity as well as kinase selectivity profiling of **34h**. Crystallographic analysis of compounds **15b**, **24b**, **24c**, **34e**, **39** bound to MPS1. This material is available free of charge *via* the Internet at <http://pubs.acs.org>.

Ascension codes

Atomic coordinates and structure factors for compounds **4**, **15b**, **24b**, **24c**, **34e** and **39** can be accessed using PBD codes 4C4J, 5EI6, 5EI2, 5EI8, 5EH0, 5EHY respectively.

AUTHOR INFORMATION

Corresponding Author

\* Telephone +44 (0)2087224353; E-mail: [swen.hoelder@icr.ac.uk](mailto:swen.hoelder@icr.ac.uk)

Notes

The authors declare the following competing financial interest(s): The authors are current or former employees of The Institute of Cancer Research, which has a commercial interest in the development of kinase inhibitors.

ACKNOWLEDGMENTS

This work was supported by Cancer Research UK [grant number C309/A11566]. We also acknowledge the Cancer Research Technology Pioneer Fund and Sixth Element Capital for funding (to PI) and NHS funding to the NIHR Biomedical Research Centre. S.L. is also supported by Breakthrough Breast Cancer (recently merged with Breast Cancer Campaign forming Breast Cancer Now). We thank Dr. Amin Mirza, Dr. Maggie Liu, and Mr. Meirion Richards for their help with LC, NMR, and mass spectrometry.

ABBREVIATIONS

CDK2, cyclin-dependent kinase 2; Cl, clearance; hERG, human Ether-à-go-go-Related Gene; HLM, human liver microsomes; L.E., ligand efficiency; MLM, mouse liver microsomes; MPS1, monopolar spindle kinase 1; MSD, MesoScale Discovery; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; PARP, poly ADP ribose polymerase; PLK1, polo-like kinase 1; PTEN, phosphatase and tensin homologue; SAC, spindle assembly checkpoint; RLM, rat liver microsomes; TGI, tumor growth inhibition; Vss, volume of distribution.

REFERENCES

1. (a) Jackson, J. R.; Patrick, D. R.; Dar, M. M.; Huang, P. S., Targeted anti-mitotic therapies: can we improve on tubulin agents? *Nat Rev Cancer* **2007,** *7*, 107-117; (b) Wood, K. W.; Cornwell, W. D.; Jackson, J. R., Past and future of the mitotic spindle as an oncology target. *Curr. Opin. Pharmacol.* **2001,** *1*, 370-377; (c) Chan, K. S.; Koh, C. G.; Li, H. Y., Mitosis-targeted anti-cancer therapies: where they stand. *Cell Death Dis* **2012,** *3*, e411.

2. (a) Hardwick, K. G., The spindle checkpoint. *Trends Genet.* **1998,** *14*, 1-4; (b) Mills, G. B.; Schmandt, R.; McGill, M.; Amendola, A.; Hill, M.; Jacobs, K.; May, C.; Rodricks, A. M.; Campbell, S.; Hogg, D., Expression of TTK, a novel human protein kinase, is associated with cell proliferation. *J. Biol. Chem.* **1992,** *267*, 16000-16006; (c) Lauze, E.; Stoelcker, B.; Luca, F. C.; Weiss, E.; Schutz, A. R.; Winey, M., Yeast spindle pole body duplication gene MPS1 encodes an essential dual specificity protein kinase. *EMBO J.* **1995,** *14*, 1655-1663; (d) Musacchio, A.; Salmon, E. D., The spindle-assembly checkpoint in space and time. *Nat. Rev. Mol. Cell Biol.* **2007,** *8*, 379-393.

3. (a) Daniel, J.; Coulter, J.; Woo, J.-H.; Wilsbach, K.; Gabrielson, E., High levels of the Mps1 checkpoint protein are protective of aneuploidy in breast cancer cells. *Proc. Natl. Acad. Sci. U. S. A.* **2011,** *108*, 5384-5389; (b) Brough, R.; Frankum, J. R.; Sims, D.; MacKay, A.; Mendes-Pereira, A. M.; Bajrami, I.; Costa-Cabral, S.; Rafiq, R.; Ahmad, A. S.; Cerone, M. A.; Natrajan, R.; Sharpe, R.; Shiu, K.-K.; Wetterskog, D.; Dedes, K. J.; Lambros, M. B.; Rawjee, T.; Linardopoulos, S.; Reis-Filho, J. S.; Turner, N. C.; Lord, C. J.; Ashworth, A., Functional Viability Profiles of Breast Cancer. *Cancer Discovery* **2011,** *1*, 260-273; (c) Gordon, D. J.; Resio, B.; Pellman, D., Causes and consequences of aneuploidy in cancer. *Nat. Rev. Genet.* **2012,** *13*, 189-203.

4. (a) Yuan, B.; Xu, Y.; Woo, J.-H.; Wang, Y.; Bae, Y. K.; Yoon, D.-S.; Wersto, R. P.; Tully, E.; Wilsbach, K.; Gabrielson, E., Increased Expression of Mitotic Checkpoint Genes in Breast Cancer Cells with Chromosomal Instability. *Clin. Cancer Res.* **2006,** *12*, 405-410; (b) Mizukami, Y.; Kono, K.; Daigo, Y.; Takano, A.; Tsunoda, T.; Kawaguchi, Y.; Nakamura, Y.; Fujii, H., Detection of novel cancer-testis antigen-specific T-cell responses in TIL, regional lymph nodes, and PBL in patients with esophageal squamous cell carcinoma. *Cancer Sci.* **2008,** *99*, 1448-1454; (c) Salvatore, G.; Nappi, T. C.; Salerno, P.; Jiang, Y.; Garbi, C.; Ugolini, C.; Miccoli, P.; Basolo, F.; Castellone, M. D.; Cirafici, A. M.; Melillo, R. M.; Fusco, A.; Bittner, M. L.; Santoro, M., A Cell Proliferation and Chromosomal Instability Signature in Anaplastic Thyroid Carcinoma. *Cancer Res.* **2007,** *67*, 10148-10158; (d) Thykjaer, T.; Workman, C.; Kruhoffer, M.; Demtroder, K.; Wolf, H.; Andersen, L. D.; Frederiksen, C. M.; Knudsen, S.; Orntoft, T. F., Identification of gene expression patterns in superficial and invasive human bladder cancer. *Cancer Res.* **2001,** *61*, 2492-2499.

5. (a) Tannous, B. A.; Kerami, M.; Van der Stoop, P. M.; Kwiatkowski, N.; Wang, J.; Zhou, W.; Kessler, A. F.; Lewandrowski, G.; Hiddingh, L.; Sol, N.; Lagerweij, T.; Wedekind, L.; Niers, J. M.; Barazas, M.; Nilsson, R. J. A.; Geerts, D.; De Witt Hamer, P. C.; Hagemann, C.; Vandertop, W. P.; Van Tellingen, O.; Noske, D. P.; Gray, N. S.; Würdinger, T., Effects of the Selective MPS1 Inhibitor MPS1-IN-3 on Glioblastoma Sensitivity to Antimitotic Drugs. *J. Nat. Canc. Inst.* **2013,** *105*, 1322-1331; (b) Slee, R. B.; Grimes, B. R.; Bansal, R.; Gore, J.; Blackburn, C.; Brown, L.; Gasaway, R.; Jeong, J.; Victorino, J.; March, K. L.; Colombo, R.; Herbert, B. S.; Korc, M., Selective inhibition of pancreatic ductal adenocarcinoma cell growth by the mitotic MPS1 kinase inhibitor NMS-P715. *Mol. Cancer. Ther.* **2014,** *13*, 307-315.

6. Aarts, M.; Linardopoulos, S.; Turner, N. C., Tumour selective targeting of cell cycle kinases for cancer treatment. *Curr. Opin. Pharmacol.* **2013,** *13*, 529-535.

7. (a) Kusakabe, K.-i.; Ide, N.; Daigo, Y.; Tachibana, Y.; Itoh, T.; Yamamoto, T.; Hashizume, H.; Hato, Y.; Higashino, K.; Okano, Y.; Sato, Y.; Inoue, M.; Iguchi, M.; Kanazawa, T.; Ishioka, Y.; Dohi, K.; Kido, Y.; Sakamoto, S.; Yasuo, K.; Maeda, M.; Higaki, M.; Ueda, K.; Yoshizawa, H.; Baba, Y.; Shiota, T.; Murai, H.; Nakamura, Y., Indazole-Based Potent and Cell-Active Mps1 Kinase Inhibitors: Rational Design from Pan-Kinase Inhibitor Anthrapyrazolone (SP600125). *J. Med. Chem.* **2013,** *56*, 4343-4356; (b) Hewitt, L.; Tighe, A.; Santaguida, S.; White, A. M.; Jones, C. D.; Musacchio, A.; Green, S.; Taylor, S. S., Sustained Mps1 activity is required in mitosis to recruit O-Mad2 to the Mad1-C-Mad2 core complex. *J. Cell Biol.* **2010,** *190*, 25-34; (c) Langdon, S. R.; Westwood, I. M.; van Montfort, R. L. M.; Brown, N.; Blagg, J., Scaffold-Focused Virtual Screening: Prospective Application to the Discovery of TTK Inhibitors. *J. Chem. Inf. Model.* **2013,** *53*, 1100-1112; (d) Chu, M. L. H.; Chavas, L. M. G.; Douglas, K. T.; Eyers, P. A.; Tabernero, L., Crystal Structure of the Catalytic Domain of the Mitotic Checkpoint Kinase Mps1 in Complex with SP600125. *J. Biol. Chem.* **2008,** *283*, 21495-21500; (e) Kwiatkowski, N.; Jelluma, N.; Filippakopoulos, P.; Soundararajan, M.; Manak, M. S.; Kwon, M.; Choi, H. G.; Sim, T.; Deveraux, Q. L.; Rottmann, S.; Pellman, D.; Shah, J. V.; Kops, G. J. P. L.; Knapp, S.; Gray, N. S., Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function. *Nat. Chem. Biol.* **2010,** *6*, 359-368; (f) Santaguida, S.; Tighe, A.; D'Alise, A. M.; Taylor, S. S.; Musacchio, A., Dissecting the role of MPS1 in chromosome biorientation and the spindle checkpoint through the small molecule inhibitor reversine. *J. Cell Biol.* **2010,** *190*, 73-87; (g) Kusakabe, K.-i.; Ide, N.; Daigo, Y.; Itoh, T.; Yamamoto, T.; Kojima, E.; Mitsuoka, Y.; Tadano, G.; Tagashira, S.; Higashino, K.; Okano, Y.; Sato, Y.; Inoue, M.; Iguchi, M.; Kanazawa, T.; Ishioka, Y.; Dohi, K.; Kido, Y.; Sakamoto, S.; Ando, S.; Maeda, M.; Higaki, M.; Yoshizawa, H.; Murai, H.; Nakamura, Y., A unique hinge binder of extremely selective aminopyridine-based Mps1 (TTK) kinase inhibitors with cellular activity. *Bioorg. Med. Chem.* **2015,** *23*, 2247-2260.

8. Tardif, K. D.; Rogers, A.; Cassiano, J.; Roth, B. L.; Cimbora, D. M.; McKinnon, R.; Peterson, A.; Douce, T. B.; Robinson, R.; Dorweiler, I.; Davis, T.; Hess, M. A.; Ostanin, K.; Papac, D. I.; Baichwal, V.; McAlexander, I.; Willardsen, J. A.; Saunders, M.; Christophe, H.; Kumar, D. V.; Wettstein, D. A.; Carlson, R. O.; Williams, B. L., Characterization of the Cellular and Antitumor Effects of MPI-0479605, a Small-Molecule Inhibitor of the Mitotic Kinase Mps1. *Mol. Cancer Ther.* **2011,** *10*, 2267-2275.

9. (a) Caldarelli, M.; Angiolini, M.; Disingrini, T.; Donati, D.; Guanci, M.; Nuvoloni, S.; Posteri, H.; Quartieri, F.; Silvagni, M.; Colombo, R., Synthesis and SAR of new pyrazolo[4,3-*h*]quinazoline-3-carboxamide derivatives as potent and selective MPS1 kinase inhibitors. *Bioorg. Med. Chem. Lett.* **2011,** *21*, 4507-4511; (b) Colombo, R.; Caldarelli, M.; Mennecozzi, M.; Giorgini, M. L.; Sola, F.; Cappella, P.; Perrera, C.; Depaolini, S. R.; Rusconi, L.; Cucchi, U.; Avanzi, N.; Bertrand, J. A.; Bossi, R. T.; Pesenti, E.; Galvani, A.; Isacchi, A.; Colotta, F.; Donati, D.; Moll, J., Targeting the Mitotic Checkpoint for Cancer Therapy with NMS-P715, an Inhibitor of MPS1 Kinase. *Cancer Res.* **2010,** *70*, 10255-10264.

10. Naud, S.; Westwood, I. M.; Faisal, A.; Sheldrake, P.; Bavetsias, V.; Atrash, B.; Cheung, K.-M. J.; Liu, M.; Hayes, A.; Schmitt, J.; Wood, A.; Choi, V.; Boxall, K.; Mak, G.; Gurden, M.; Valenti, M.; de Haven Brandon, A.; Henley, A.; Baker, R.; McAndrew, C.; Matijssen, B.; Burke, R.; Hoelder, S.; Eccles, S. A.; Raynaud, F. I.; Linardopoulos, S.; van Montfort, R. L. M.; Blagg, J., Structure-Based Design of Orally Bioavailable 1*H*-Pyrrolo[3,2-*c*]pyridine Inhibitors of Mitotic Kinase Monopolar Spindle 1 (MPS1). *J. Med. Chem.* **2013,** *56*, 10045-10065.

11. Liu, Y.; Lang, Y.; Patel, N. K.; Ng, G.; Laufer, R.; Li, S.-W.; Edwards, L.; Forrest, B.; Sampson, P. B.; Feher, M.; Ban, F.; Awrey, D. E.; Beletskaya, I.; Mao, G.; Hodgson, R.; Plotnikova, O.; Qiu, W.; Chirgadze, N. Y.; Mason, J. M.; Wei, X.; Lin, D. C.-C.; Che, Y.; Kiarash, R.; Madeira, B.; Fletcher, G. C.; Mak, T. W.; Bray, M. R.; Pauls, H. W., The discovery of orally bioavailable tyrosine threonine kinase (TTK) inhibitors: 3-(4-(heterocyclyl)phenyl)-1*H*-indazole-5-carboxamides as anticancer agents. *J. Med. Chem.* **2015,** *58*, 3366-3392.

12. (a) Kusakabe, K.-i.; Ide, N.; Daigo, Y.; Itoh, T.; Higashino, K.; Okano, Y.; Tadano, G.; Tachibana, Y.; Sato, Y.; Inoue, M.; Wada, T.; Iguchi, M.; Kanazawa, T.; Ishioka, Y.; Dohi, K.; Tagashira, S.; Kido, Y.; Sakamoto, S.; Yasuo, K.; Maeda, M.; Yamamoto, T.; Higaki, M.; Endoh, T.; Ueda, K.; Shiota, T.; Murai, H.; Nakamura, Y., Diaminopyridine-Based Potent and Selective Mps1 Kinase Inhibitors Binding to an Unusual Flipped-Peptide Conformation. *ACS Med. Chem. Lett.* **2012,** *3*, 560-564; (b) Kusakabe, K.-i.; Ide, N.; Daigo, Y.; Itoh, T.; Yamamoto, T.; Hashizume, H.; Nozu, K.; Yoshida, H.; Tadano, G.; Tagashira, S.; Higashino, K.; Okano, Y.; Sato, Y.; Inoue, M.; Iguchi, M.; Kanazawa, T.; Ishioka, Y.; Dohi, K.; Kido, Y.; Sakamoto, S.; Ando, S.; Maeda, M.; Higaki, M.; Baba, Y.; Nakamura, Y., Discovery of Imidazo[1,2-*b*]pyridazine Derivatives: Selective and Orally Available Mps1 (TTK) Kinase Inhibitors Exhibiting Remarkable Antiproliferative Activity. *J. Med. Chem.* **2015,** *58*, 1760-1775.

13. Laufer, R.; Ng, G.; Liu, Y.; Patel, N. K. B.; Edwards, L. G.; Lang, Y.; Li, S.-W.; Feher, M.; Awrey, D. E.; Leung, G.; Beletskaya, I.; Plotnikova, O.; Mason, J. M.; Hodgson, R.; Wei, X.; Mao, G.; Luo, X.; Huang, P.; Green, E.; Kiarash, R.; Lin, D. C.-C.; Harris-Brandts, M.; Ban, F.; Nadeem, V.; Mak, T. W.; Pan, G. J.; Qiu, W.; Chirgadze, N. Y.; Pauls, H. W., Discovery of inhibitors of the mitotic kinase TTK based on *N*-(3-(3-sulfamoylphenyl)-1*H*-indazol-5-yl)acetamides and carboxamides. *Bioorg. Med. Chem.* **2014,** *22*, 4968-4997.

14. (a) Martinez, R.; Blasina, A.; Hallin, J. F.; Hu, W.; Rymer, I.; Fan, J.; Hoffman, R. L.; Murphy, S.; Marx, M.; Yanochko, G.; Trajkovic, D.; Dinh, D.; Timofeevski, S.; Zhu, Z.; Sun, P.; Lappin, P. B.; Murray, B. W., Mitotic Checkpoint Kinase Mps1 Has a Role in Normal Physiology which Impacts Clinical Utility. *PLoS ONE* **2015,** *10*, e0138616; (b) Wengner, A. M.; Siemeister, G. Combination of a imidazopyridazine derivative and a mitotic agent for the treatment of cancer. WO2014198776A1 2014; (c) Wengner, A. M.; Siemeister, G. Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor. WO2014198645, 2014; (d) Maia, A. R. R.; de Man, J.; Boon, U.; Janssen, A.; Song, J.-Y.; Omerzu, M.; Sterrenburg, J. G.; Prinsen, M. B. W.; Willemsen-Seegers, N.; de Roos, J. A. D. M.; van Doornmalen, A. M.; Uitdehaag, J. C. M.; Kops, G. J. P. L.; Jonkers, J.; Buijsman, R. C.; Zaman, G. J. R.; Medema, R. H., Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model. *Annals of Oncology* **2015**.

15. Hopkins, A. L.; Groom, C. R.; Alex, A., Ligand efficiency: a useful metric for lead selection. *Drug Disc. Today* **2004,** *9*, 430-431.

16. Innocenti, P.; Woodward, H.; O'Fee, L.; Hoelder, S., Expanding the scope of fused pyrimidines as kinase inhibitor scaffolds: synthesis and modification of pyrido[3,4-*d*]pyrimidines. *Org. Biomol. Chem.* **2015,** *13*, 893-904.

17. Bavetsias, V.; Atrash, B.; Naud, S. G. A.; Sheldrake, P. W.; Blagg, J. Preparation of pyrrolopyridinamine derivatives as Mps1 inhibitors. WO2012123745A1, 2012/09/20/, 2012.

18. Picture created using The PyMol Molecular Graphics System version 1.5.0.5.

19. Lovering, F.; Bikker, J.; Humblet, C., Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success. *J. Med. Chem.* **2009,** *52*, 6752-6756.

20. Copeland, R. A., *Evaluation of Enzyme Inhibitors in Drug Discovery*. Wiley: Hoboken, New Jersey, 2005; Vol. 46.

21. (a) Ajiro, K.; Nishimoto, T., Specific site of histone H3 phosphorylation related to the maintenance of premature chromosome condensation. Evidence for catalytically induced interchange of the subunits. *J. Biol. Chem.* **1985,** *260*, 15379-15381; (b) Juan, G.; Traganos, F.; James, W. M.; Ray, J. M.; Roberge, M.; Sauve, D. M.; Anderson, H.; Darzynkiewicz, Z., Histone H3 phosphorylation and expression of cyclins A and B1 measured in individual cells during their progression through G2 and mitosis. *Cytometry* **1998,** *32*, 71-77.

22. Kabsch, W., Software XDS for image rotation, recognition and crystal symmetry assignment. *Acta Crystallogr., Sect. D: Biol. Crystallogr.* **2010,** *66*, 125-132.

23. Winn, M. D.; Ballard, C. C.; Cowtan, K. D.; Dodson, E. J.; Emsley, P.; Evans, P. R.; Keegan, R. M.; Krissinel, E. B.; Leslie, A. G. W.; McCoy, A.; McNicholas, S. J.; Murshudov, G. N.; Pannu, N. S.; Potterton, E. A.; Powell, H. R.; Read, R. J.; Vagin, A.; Wilson, K. S., Overview of the CCP4 suite and current developments. *Acta Crystallogr., Sect. D: Biol. Crystallogr.* **2011,** *67*, 235-242.

24. Evans, P., Scaling and assessment of data quality. *Acta Crystallogr., Sect. D: Biol. Crystallogr.* **2006,** *62*, 72-82.

25. McCoy, A. J.; Grosse-Kunstleve, R. W.; Adams, P. D.; Winn, M. D.; Storoni, L. C.; Read, R. J., Phaser crystallographic software. *J. Appl. Crystallogr.* **2007,** *40*, 658-674.

26. Emsley, P.; Cowtan, K., Coot: model-building tools for molecular graphics. *Acta Crystallogr., Sect. D: Biol. Crystallogr.* **2004,** *60*, 2126-2132.

27. Bricogne, G.; Blanc, E.; Brandl, M.; Flensburg, C.; Keller, P.; Paciorek, W.; Roversi, P.; Sharff, A.; Smart, O. S.; Vonrhein, C.; Womack, T. O., BUSTER, version 2.11.4; Global Phasing Ltd.: Cambridge, United Kingdom. **2012**.

28. Adams, P. D.; Afonine, P. V.; Bunkóczi, G.; Chen, V. B.; Davis, I. W.; Echols, N.; Headd, J. J.; Hung, L.-W.; Kapral, G. J.; Grosse-Kunstleve, R. W.; McCoy, A. J.; Moriarty, N. W.; Oeffner, R.; Read, R. J.; Richardson, D. C.; Richardson, J. S.; Terwilliger, T. C.; Zwart, P. H., PHENIX: a comprehensive Python-based system for macromolecular structure solution. **2010,** *D66*, 213–221.

29. Smart, O. S.; Womack, T. O.; Sharff, A.; Flensburg, C.; Keller, P.; Paciorek, W.; Vonrhein, C.; Bricogne, G., Grade, version 1.2.1; Global Phasing Ltd.: Cambridge, United Kingdom. **2012**.

30. Bruno, I. J.; Cole, J. C.; Lommerse, J. P. M.; Rowland, R. S.; Taylor, R.; Verdonk, M. L., Isostar: a library of information about nonbonded interactions. *J. Comput. Aided Mol. Des.* **1997,** *11*, 525-537.

31. Davis, I. W.; Leaver-Fay, A.; Chen, V. B.; Block, J. N.; Kapral, G. J.; Wang, X.; Murray, L. W.; Arendall, W. B.; Snoeyink, J.; Richardson, J. S.; Richardson, D. C., MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. *Nucleic Acids Research* **2007,** *35*, W375-W383.

32. Workman, P.; Aboagye, E. O.; Balkwill, F.; Balmain, A.; Bruder, G.; Chaplin, D. J.; Double, J. A.; Everitt, J.; Farningham, D. A. H.; Glennie, M. J.; Kelland, L. R.; Robinson, V.; Stratford, I. J.; Tozer, G. M.; Watson, S.; Wedge, S. R.; Eccles, S. A., Guidelines for the welfare and use of animals in cancer research. *Br J Cancer* **2010,** *102*, 1555-1577.

For Table of contents only

